Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03905694
Previous Study | Return to List | Next Study

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03905694
Recruitment Status : Recruiting
First Posted : April 5, 2019
Last Update Posted : July 11, 2019
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).

Condition or disease Intervention/treatment Phase
Primary Hyperoxaluria Primary Hyperoxaluria Type 1 (PH1) Drug: Lumasiran Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Actual Study Start Date : April 22, 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : February 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lumasiran
Participants will receive lumasiran during the study.
Drug: Lumasiran
Lumasiran will be administered by subcutaneous (SC) injection.
Other Name: ALN-GO1




Primary Outcome Measures :
  1. Percentage Change in Urinary Oxalate Excretion from Baseline to Month 6 [ Time Frame: Up to 6 months ]

Secondary Outcome Measures :
  1. Percentage Change in Urinary Oxalate Excretion from Baseline to End of Study (Month 60) [ Time Frame: Up to 60 months ]
  2. Absolute Change in Urinary Oxalate Excretion from Baseline [ Time Frame: Up to 60 months ]
  3. Percentage of Participants with Urinary Oxalate Excretion ≤ the Upper Limit of Normal (ULN) and ≤ 1.5 x ULN [ Time Frame: Up to 60 months ]
  4. Maximum Observed Plasma Concentration (Cmax) of Lumasiran [ Time Frame: Up to 24 months ]
  5. Time to Maximum Observed Plasma Concentration (tmax) of Lumasiran [ Time Frame: Up to 24 months ]
  6. Elimination Half-life (t1/2beta) of Lumasiran [ Time Frame: Up to 24 months ]
  7. Area Under the Concentration-time Curve (AUC) of Lumasiran [ Time Frame: Up to 24 months ]
  8. Apparent Clearance (CL/F) of Lumasiran [ Time Frame: Up to 24 months ]
  9. Apparent Volume of Distribution (V/F) of Lumasiran [ Time Frame: Up to 24 months ]
  10. Change in Estimated Glomerular Filtration Rate (eGFR) from Baseline [ Time Frame: Up to 60 months ]
  11. Frequency of Adverse Events (AEs) [ Time Frame: Up to 60 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has confirmation of primary hyperoxaluria type 1 (PH1)
  • Meets urinary oxalate excretion requirements
  • If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days

Exclusion Criteria:

  • Abnormal serum creatinine levels at screening for infants who are less than 1 year old
  • Does not have relatively preserved kidney function
  • Clinical evidence of systemic oxalosis
  • History of kidney or liver transplant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03905694


Contacts
Layout table for location contacts
Contact: Alnylam Clinical Trial Information Line 1-877-ALNYLAM clinicaltrials@alnylam.com
Contact: Alnylam Clinical Trial Information Line 1-877-256-9526 clinicaltrials@alnylam.com

Locations
Layout table for location information
United States, Texas
Clinical Trial Site Recruiting
Houston, Texas, United States, 77030
France
Clinical Trial Site Recruiting
Lyon, France
Clinical Trial Site Recruiting
Paris, France
Germany
Clinical Trial Site Recruiting
Bonn, Germany
Israel
Clinical Trial Site Recruiting
Jerusalem, Israel
United Kingdom
Clinical Trial Site Recruiting
London, United Kingdom
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Tracy McGregor, MD, MSCI Alnylam Pharmaceuticals

Layout table for additonal information
Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03905694     History of Changes
Other Study ID Numbers: ALN-GO1-004
2018-004014-17 ( EudraCT Number )
First Posted: April 5, 2019    Key Record Dates
Last Update Posted: July 11, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Alnylam Pharmaceuticals:
PH1
Primary Hyperoxaluria
Hyperoxaluria
RNAi Therapeutic
siRNA
AGT

Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperoxaluria, Primary
Hyperoxaluria
Kidney Diseases
Urologic Diseases
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases